Corticosteroids in brain cancer patients: benefits and pitfalls

References

• Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. Lancet81, 46–53 (1961).
   Web of Science ®Google Scholar
• Ryken TC, McDermott M, Robinson PD et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol.96(1), 103–114 (2010).
   PubMed Web of Science ®Google Scholar
• Ingraham FD, Matson DD, Mc Laurin RL. Cortisone and ACTH as an adjunct to the surgery of craniopharyngiomas. N. Engl. J. Med.246(15), 568–571 (1952).
   PubMed Web of Science ®Google Scholar
• Kofman S, Garvin JS, Nagamani D, Taylor SG 3rd. Treatment of cerebral metastases from breast carcinoma with prednisolone. J. Am. Med. Assoc.163(16), 1473–1476 (1957).
   PubMedGoogle Scholar
• Bell BA, Smith MA, Kean DM et al. Brain water measured by magnetic resonance imaging. Correlation with direct estimation and changes after mannitol and dexamethasone. Lancet1(8524), 66–69 (1987).
   PubMedGoogle Scholar
• Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol.11(11), 1096–1106 (2010).
   PubMed Web of Science ®Google Scholar
• Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N. Engl. J. Med.311(9), 549–552 (1984).
   PubMed Web of Science ®Google Scholar
• Todd FD 2nd, Miller CA, Yates AJ, Mervis LJ. Steroid-induced remission in primary malignant lymphoma of the central nervous system. Surg. Neurol.26(1), 79–84 (1986).
   PubMedGoogle Scholar
• Ryken TC, McDermott M, Robinson PD et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol.96(1), 103–114 (2010).
   PubMed Web of Science ®Google Scholar
• Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose–effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology44(4), 675–680 (1994).
   PubMed Web of Science ®Google Scholar
• Graham PH, Capp A, Delaney G et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin. Oncol. (R. Coll. Radiol.)18(1), 70–76 (2006).
   PubMed Web of Science ®Google Scholar
• Marantidou A, Levy C, Duquesne A et al. Steroid requirements during radiotherapy for malignant gliomas. J. Neurooncol.100(1), 89–94 (2010).
   PubMed Web of Science ®Google Scholar
• Miller JD, Leech P. Effects of mannitol and steroid therapy on intracranial volume–pressure relationships in patients. J. Neurosurg.42(3), 274–281 (1975).
   PubMed Web of Science ®Google Scholar
• Miller JD, Sakalas R, Ward JD et al. Methylprednisolone treatment in patients with brain tumors. Neurosurgery1(2), 114–117 (1977).
   PubMedGoogle Scholar
• Yeung WT, Lee TY, Del Maestro RF, Kozak R, Bennett J, Brown T. Effect of steroids on iopamidol blood–brain transfer constant and plasma volume in brain tumors measured with x-ray computed tomography. J. Neurooncol.18(1), 53–60 (1994).
   PubMedGoogle Scholar
• Gutin PH. Corticosteroid therapy in patients with cerebral tumors: benefits, mechanisms, problems, practicalities. Semin. Oncol.2(1), 49–56 (1975).
   PubMedGoogle Scholar
• Sturdza A, Millar BA, Bana N et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer16(9), 1041–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr. Opin. Neurol.23(6), 597–602 (2010).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol. Allergy Clin. North Am.25(3), 451–468 (2005).
   PubMed Web of Science ®Google Scholar
• Karssen AM, de Kloet ER. Synthetic glucocorticoids. In: Encyclopedia of Stress. Fink G (Ed.). Academic Press, CA, USA 566–570 (2000).
   Google Scholar
• Cosio BG, Torrego A, Adcock IM. [Molecular mechanisms of glucocorticoids]. Arch. Bronconeumol.41(1), 34–41 (2005).
   PubMedGoogle Scholar
• Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids75(1), 1–12 (2010).
   PubMed Web of Science ®Google Scholar
• Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol.83(1–5), 37–48 (2002).
   PubMed Web of Science ®Google Scholar
• Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg. Clin. N. Am.7(3), 435–446 (1996).
   PubMedGoogle Scholar
• Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J. Neurooncol.80(3), 313–332 (2006).
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience129(4), 1011–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Machein MR, Plate KH. VEGF in brain tumors. J. Neurooncol.50(1–2), 109–120 (2000).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int. J. Dev. Neurosci.17(5–6), 517–530 (1999).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Black KL. Peritumoral edema. In: The Gliomas. Berger MS, Wilson CB (Eds). WB Saunders, PA, USA, 107–114 (1999).
   Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol.1(3), 223–236 (2006).
   PubMed Web of Science ®Google Scholar
• Hedley-Whyte ET, Hsu DW. Effect of dexamethasone on blood-brain barrier in the normal mouse. Ann. Neurol.19(4), 373–377 (1986).
   PubMedGoogle Scholar
• Heiss JD, Papavassiliou E, Merrill MJ et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J. Clin. Invest.98(6), 1400–1408 (1996).
   PubMed Web of Science ®Google Scholar
• Forster C, Silwedel C, Golenhofen N et al. Occludin as direct target for glucocorticoid-induced improvement of blood–brain barrier properties in a murine in vitro system. J. Physiol.565(Pt 2), 475–486 (2005).
   PubMedGoogle Scholar
• Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte–endothelial interactions by glucocorticoids. Ann. NY Acad. Sci.966, 108–118 (2002).
   PubMed Web of Science ®Google Scholar
• Blecharz KG, Drenckhahn D, Forster CY. Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J. Cereb. Blood Flow Metab.28(6), 1139–1149 (2008).
   PubMedGoogle Scholar
• Koehler PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs6(1), 19–33 (1995).
   PubMedGoogle Scholar
• Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N. Engl. J. Med.294(9), 473–479 (1976).
   PubMed Web of Science ®Google Scholar
• Carson JL, Strom BL, Schinnar R, Duff A, Sim E. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am. J. Med.91(3), 223–228 (1991).
   PubMedGoogle Scholar
• Conn HO, Poynard T. Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J. Chronic Dis.38(6), 457–468 (1985).
   PubMedGoogle Scholar
• Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology41(8), 1235–1239 (1991).
   PubMedGoogle Scholar
• Vick NA. Steroid toxicity. J. Neurooncol.6(2), 199 (1988).
   PubMedGoogle Scholar
• Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am. J. Med.61(4), 485–492 (1976).
   PubMed Web of Science ®Google Scholar
• Kelly FJ, McGrath JA, Goldspink DF, Cullen MJ. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve9(1), 1–10 (1986).
   PubMed Web of Science ®Google Scholar
• Koski CL, Rifenberick DH, Max SR. Oxidative metabolism of skeletal muscle in steroid atrophy. Arch. Neurol.31(6), 407–410 (1974).
   PubMedGoogle Scholar
• Ruff RL, Weissmann J. Endocrine myopathies. Neurol. Clin.6(3), 575–592 (1988).
   PubMed Web of Science ®Google Scholar
• Kimura K, Kanda F, Okuda S, Chihara K. Insulin-like growth factor 1 inhibits glucocorticoid-induced glutamine synthetase activity in cultured L6 rat skeletal muscle cells. Neurosci. Lett.302(2–3), 154–156 (2001).
   PubMedGoogle Scholar
• Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol. Rep.57(1), 23–34 (2005).
   PubMed Web of Science ®Google Scholar
• Layzer RB. Neuromuscular Manifestations of Systemic Disease. Plum F, Baringer JR, Gilman S (Eds). FA Davis Company, PA, USA (1985).
   Google Scholar
• Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med.350(24), 2487–2498 (2004).
   Google Scholar
• Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature334(6182), 519–522 (1988).
   PubMed Web of Science ®Google Scholar
• Henson JW, Jalaj JK, Walker RW, Stover DE, Fels AO. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch. Neurol.48(4), 406–409 (1991).
   PubMed Web of Science ®Google Scholar
• Mathew BS, Grossman SA. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat. Rev.29(2), 105–119 (2003).
   PubMed Web of Science ®Google Scholar
• Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J. Neurooncol.27(3), 235–240 (1996).
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA267(6), 832–837 (1992).
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. (Hoboken)62(11), 1515–1526 (2010).
   PubMed Web of Science ®Google Scholar
• Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin. Biol. Ther.5(6), 817–832 (2005).
   PubMed Web of Science ®Google Scholar
• Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann. Allergy62(5), 375–391 (1989).
   PubMedGoogle Scholar
• Cifone MG, Migliorati G, Parroni R et al. Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. Blood93(7), 2282–2296 (1999).
   PubMed Web of Science ®Google Scholar
• Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci.63(1), 60–72 (2006).
   PubMed Web of Science ®Google Scholar
• Franchimont D, Galon J, Gadina M et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. Immunol.164(4), 1768–1774 (2000).
   PubMed Web of Science ®Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol.120(2–3), 69–75 (2010).
   PubMed Web of Science ®Google Scholar
• Kaup B, Schindler I, Knupfer H, Schlenzka A, Preiss R, Knupfer MM. Time-dependent inhibition of glioblastoma cell proliferation by dexamethasone. J. Neurooncol.51(2), 105–110 (2001).
   PubMed Web of Science ®Google Scholar
• McLean JS, Frame MC, Freshney RI, Vaughan PF, Mackie AE, Singer I. Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents. Anticancer Res.6(5), 1101–1106 (1986).
   PubMedGoogle Scholar
• Sundberg M, Savola S, Hienola A, Korhonen L, Lindholm D. Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1. J. Neurosci.26(20), 5402–5410 (2006).
   PubMed Web of Science ®Google Scholar
• Kim JB, Ju JY, Kim JH et al. Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro. Brain Res.1027(1–2), 1–10 (2004).
   PubMed Web of Science ®Google Scholar
• Sabolek M, Herborg A, Schwarz J, Storch A. Dexamethasone blocks astroglial differentiation from neural precursor cells. Neuroreport17(16), 1719–1723 (2006).
   PubMedGoogle Scholar
• Yu IT, Lee SH, Lee YS, Son H. Differential effects of corticosterone and dexamethasone on hippocampal neurogenesis in vitro. Biochem. Biophys. Res. Commun.317(2), 484–490 (2004).
   PubMedGoogle Scholar
• Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing’s syndrome. J. Int. Neuropsychol. Soc.6(1), 20–29 (2000).
   PubMedGoogle Scholar
• Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J. Neurol. Neurosurg. Psychiatry47(10), 1087–1090 (1984).
   PubMed Web of Science ®Google Scholar
• Choi Y, Thrasher K, Werk EE Jr, Sholiton LJ, Olinger C. Effect of diphenylhydantoin on cortisol kinetics in humans. J. Pharmacol. Exp. Ther.176(1), 27–34 (1971).
   PubMedGoogle Scholar
• Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J. Clin. Endocrinol. Metab.34(1), 44–50 (1972).
   PubMed Web of Science ®Google Scholar
• Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med. Wkly132(29–30), 425–426 (2002).
   PubMedGoogle Scholar
• Ruff RL. Endocrine myopathies. In: Myology: Basic and Clinical. Banker BQ, Engle AG (Eds). McGraw-Hill, NY, USA, 1871–1879 (1986).
   Google Scholar
• Penry JK, Newmark ME. The use of antiepileptic drugs. Ann. Intern. Med.90(2), 207–218 (1979).
   PubMed Web of Science ®Google Scholar
• Das A, Banik NL, Patel SJ, Ray SK. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol. Cancer3(1), 36 (2004).
   PubMed Web of Science ®Google Scholar
• Tjuvajev J, Uehara H, Desai R et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res.56(6), 1352–1360 (1996).
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA, Eckardt J, Burris H et al. A Phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann. Oncol.9(1), 71–77 (1998).
   PubMed Web of Science ®Google Scholar
• Hariharan S, Shapiro W, Chang S et al. Phase II randomized dose-ranging trial of human corticotrophin releasing factor in symptomatic brain tumor patients. Neurology54, A12 (2000).
   Google Scholar
• Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J. Clin. Pathol.57(1), 6–13 (2004).
   PubMed Web of Science ®Google Scholar
• Portnow J, Suleman S, Grossman SA, Eller S, Carson K. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro. Oncol.4(1), 22–25 (2002).
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Duda DG, di Tomaso E et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat. Rev. Clin. Oncol.6(4), 229–236 (2009).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8(7), 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Vogelbaum MA, Wen PY, MacDonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical MacDonald’s Criteria. J. Clin. Oncol.27(18), 2905–2908 (2009).
   PubMed Web of Science ®Google Scholar